Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA; National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium..

J Natl Cancer Inst. 2007 Sep 5;99(17):1335-9. Erratum in: J Natl Cancer Inst. 2007 Oct 3;99(19):1493.

PMID:
17698950
2.

Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.

Farhat GN, Walker R, Buist DS, Onega T, Kerlikowske K.

J Clin Oncol. 2010 Dec 10;28(35):5140-6. doi: 10.1200/JCO.2010.29.5121.

3.

Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California.

Ereman RR, Prebil LA, Mockus M, Koblick K, Orenstein F, Benz C, Clarke CA.

BMC Public Health. 2010 Apr 30;10:228. doi: 10.1186/1471-2458-10-228.

4.

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.

J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61.

PMID:
17652280
5.

Obesity, mammography use and accuracy, and advanced breast cancer risk.

Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS.

J Natl Cancer Inst. 2008 Dec 3;100(23):1724-33. doi: 10.1093/jnci/djn388.

6.

Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.

Buist DS, Walker R, Bowles EJ, Carney PA, Taplin SH, Onega T, Kerlikowske K, Clinton W, Miglioretti DL.

Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):720-7. doi: 10.1158/1055-9965.EPI-11-1115.

7.

Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk.

Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R; National Institutes of Health Breast Cancer Surveillance Consortium..

J Natl Cancer Inst. 2007 Mar 7;99(5):386-95.

PMID:
17341730
8.

Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

Robbins AS, Clarke CA.

J Natl Cancer Inst. 2007 Dec 5;99(23):1815; author reply 1816-7. No abstract available.

PMID:
18042938
9.

Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy.

Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, Wernli KJ, Miglioretti DL, O'Meara ES; Breast Cancer Surveillance Consortium..

JAMA Intern Med. 2013 May 13;173(9):807-16. doi: 10.1001/jamainternmed.2013.307.

10.

Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

Anderson BO.

J Natl Cancer Inst. 2007 Dec 5;99(23):1815-6; author reply 1816-7. No abstract available.

PMID:
18042937
11.

Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

Vaidya JS.

J Natl Cancer Inst. 2008 Apr 16;100(8):598-9; author reply 599. doi: 10.1093/jnci/djn080. No abstract available.

PMID:
18398100
12.

Prospective breast cancer risk prediction model for women undergoing screening mammography.

Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K.

J Natl Cancer Inst. 2006 Sep 6;98(17):1204-14.

PMID:
16954473
13.

Breast cancer incidence and hormone replacement therapy in Canada.

De P, Neutel CI, Olivotto I, Morrison H.

J Natl Cancer Inst. 2010 Oct 6;102(19):1489-95. doi: 10.1093/jnci/djq345.

PMID:
20864685
14.

Incidence of and treatment for ductal carcinoma in situ of the breast.

Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C.

JAMA. 1996 Mar 27;275(12):913-8.

PMID:
8598618
15.

Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.

Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA.

J Clin Oncol. 2003 Dec 1;21(23):4314-21.

PMID:
14645420
16.

Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium.

Menes TS, Kerlikowske K, Jaffer S, Seger D, Miglioretti DL.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2822-8. doi: 10.1158/1055-9965.EPI-09-0745.

17.

Predicting risk of breast cancer in postmenopausal women by hormone receptor status.

Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA; Women's Health Initiative Investigators..

J Natl Cancer Inst. 2007 Nov 21;99(22):1695-705.

PMID:
18000216
18.

Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.

Caan B, Habel L, Quesenberry C, Kushi L, Herrinton L.

J Natl Cancer Inst. 2008 Apr 16;100(8):597-8; author reply 599. doi: 10.1093/jnci/djn079. No abstract available.

PMID:
18398101
19.
20.

Supplemental Content

Support Center